StockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS)

StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS) in a research note issued to investors on Tuesday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Barclays dropped their price objective on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th.

Cellectis Price Performance

Shares of NASDAQ CLLS opened at $1.81 on Tuesday. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $100.61 million, a price-to-earnings ratio of -1.39 and a beta of 3.09. Cellectis has a twelve month low of $1.41 and a twelve month high of $3.38. The business has a 50 day simple moving average of $1.84 and a 200-day simple moving average of $2.01.

Cellectis (NASDAQ:CLLS) last released its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The business had revenue of $18.05 million for the quarter, compared to the consensus estimate of $5.00 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. During the same quarter in the previous year, the firm earned ($0.31) EPS. As a group, equities research analysts expect that Cellectis will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Cellectis

A number of hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new position in shares of Cellectis during the second quarter worth about $29,000. First Affirmative Financial Network acquired a new position in Cellectis during the 3rd quarter valued at about $45,000. Principal Financial Group Inc. grew its position in Cellectis by 2.9% in the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after purchasing an additional 12,467 shares during the last quarter. Finally, Long Focus Capital Management LLC increased its stake in shares of Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after purchasing an additional 130,000 shares during the period. 63.90% of the stock is currently owned by institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.